Consumer Insights
Uncover trends and behaviors shaping consumer choices today
Procurement Insights
Optimize your sourcing strategy with key market data
Industry Stats
Stay ahead with the latest trends and market analysis.
Explore Our Diverse Range Of Offerings
From detailed reports to experts services offered in 15+
Industry Domains
Add 2 More Reports For 20% off
Report Overview
Antisense oligonucleotide therapeutics are nucleic acid-based therapies designed to regulate gene expression by targeting specific RNA sequences associated with various diseases. According to Farhad Imam et al., 2025, over 57 million people worldwide are affected by neurodegenerative diseases, with cases projected to double every 20 years, highlighting the urgent need for advanced therapeutics. As per the antisense oligonucleotide therapeutics pipeline analysis by Expert Market Research, the expanding ASO pipeline is driven by rising investments in antisense oligonucleotide drug development, increasing focus on mRNA-targeted ASO therapeutics, and advancements in splice-switching oligonucleotides (SSO) and RNase H-dependent ASOs for rare and neurological disorders.
-
Major companies involved in the antisense oligonucleotide therapeutics pipeline analysis include Laboratoires Thea, Sepul Bio, and others.
-
Leading drugs currently in the pipeline include nL-CHCHD-001, nL-LMNB1-001, nL-FLVC-001, and others.
-
Advancements in RNA-targeted therapies, increasing clinical trials for rare genetic disorders, and strategic collaborations among biopharmaceutical companies are accelerating innovation, expanding therapeutic applications, and strengthening the development landscape worldwide.
Report Coverage
The Antisense Oligonucleotide Therapeutics Pipeline Analysis Report by Expert Market Research gives comprehensive insights into antisense oligonucleotide therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for antisense oligonucleotide therapeutics. The antisense oligonucleotide therapeutics report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The antisense oligonucleotide therapeutics pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with antisense oligonucleotide therapeutics treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to antisense oligonucleotide therapeutics.
Read more about this report - Request a Free Sample
Antisense Oligonucleotide Therapeutics Pipeline Outlook
Antisense oligonucleotide therapeutics are synthetic single-stranded nucleic acid molecules developed to target specific messenger RNA sequences and regulate gene expression. These therapies work by blocking, degrading, or modifying RNA activity to reduce abnormal protein production associated with genetic and neurological disorders. Advancements in antisense oligonucleotide therapeutics pipeline analysis 2026 are expanding precision-targeted treatment approaches across multiple therapeutic areas.
Antisense oligonucleotide therapeutics work by binding to target RNA sequences and altering protein synthesis through RNA degradation, exon skipping, or splicing modulation. Therapies such as Nusinersen (Spinraza) improve survival motor neuron protein production, while Tofersen (Qalsody) reduces toxic superoxide dismutase 1 protein expression. Drugs including Eteplirsen (Exondys 51) and Golodirsen (Vyondys 53) support dystrophin restoration in Duchenne Muscular Dystrophy patients. In July 2024, the FDA highlighted advanced clinical pharmacology considerations for oligonucleotide therapeutics to improve RNA-based drug development and regulatory evaluation. Companies including Ionis Pharmaceuticals, Biogen, and Sarepta Therapeutics are progressing late-stage antisense oligonucleotide clinical trials and ASO pipeline drugs by indication and phase, strengthening the antisense drug development landscape and competitive intelligence for rare neurological diseases.
Antisense Oligonucleotide Therapeutics – Pipeline Therapeutic Assessment
This section of the report covers the analysis of antisense oligonucleotide therapeutics drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase 1)
- Preclinical and Discovery Stage Products
By Drug Class
The antisense oligonucleotide therapeutics pipeline analysis report covers 50+ drug analyses based on drug classes:
- Small Molecules
- Monoclonal Antibodies
- Gene Therapies
- Peptides
- Polymers
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration:
- Oral
- Parenteral
- Others
Antisense Oligonucleotide Therapeutics Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total antisense oligonucleotide therapeutics clinical trials. holds around 52% share, driven by expanding clinical evaluation and increasing therapeutic effectiveness across multiple indications. Phase I accounts for 43%, supported by rising research activities and novel drug candidate development. Early phase I represents 2%, while phase III contributes 3%, reflecting gradual advancement toward commercialization and future market expansion.
Antisense Oligonucleotide Therapeutics Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under the antisense oligonucleotide therapeutics pipeline analysis include small molecules, monoclonal antibodies, gene therapies, peptides, and polymers. The antisense oligonucleotide therapeutics report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for antisense oligonucleotide therapeutics. Antisense oligonucleotide therapeutics are emerging as a promising drug class for chronic hepatitis B virus treatment by targeting viral messenger RNA and inhibiting viral protein synthesis. For instance, bepirovirsen, an investigational antisense oligonucleotide developed by GSK Plc, is under evaluation for achieving functional cure in hepatitis B infections. The therapy works by suppressing viral replication and enhancing immune-mediated clearance, thereby improving long-term disease control in affected patients.
Antisense Oligonucleotide Therapeutics Clinical Trials – Key Players
The EMR report for the antisense oligonucleotide therapeuticspipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed antisense oligonucleotide therapeutics assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in antisense oligonucleotide therapeutics clinical trials:
- Laboratoires Thea
- Sepul Bio
- ProQR Therapeutics
- Vanda Pharmaceuticals
- Ultragenyx Pharmaceutical Inc.
- Amylyx Pharmaceuticals Inc.
- Stoke Therapeutics, Inc.
- Vico Therapeutics B. V.
- Bio-Path Holdings, Inc.
- Elpida Therapeutics SPC
Antisense Oligonucleotide Therapeutics – Emerging Drugs Profile
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for antisense oligonucleotide therapeutics. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of antisense oligonucleotide therapeutics drug candidates.
Drug: nL-CHCHD-001
nL-CHCHD-001 is a personalized antisense oligonucleotide (ASO) therapeutic being sponsored by the n-Lorem Foundation for the treatment of amyotrophic lateral sclerosis (ALS) associated with CHCHD10 gene mutations. The Phase 1/2 study is evaluating the safety and efficacy of this individualized ASO therapy in a single participant. The drug is designed to selectively reduce toxic CHCHD10 gene transcripts that are contributing to neuronal degeneration and mitochondrial dysfunction in ALS. The therapy is being administered as an experimental ASO treatment and is targeting the underlying genetic cause of disease progression. The study is expected to be completed by March 2027.
Drug: nL-LMNB1-001
nL-LMNB1-001 is an investigational personalized antisense oligonucleotide (ASO) therapy being sponsored by the n-Lorem Foundation for the treatment of LMNB1 mutation-associated autosomal dominant leukodystrophy (ADLD). The drug is being designed to selectively target and reduce abnormal LMNB1 gene expression, which is contributing to progressive white matter degeneration in the central nervous system. The Phase 1/2 open-label, single-participant study is examining the safety, tolerability, and efficacy of the ASO therapy. The treatment is being administered as an individualized experimental therapy, with study completion expected in March 2027.
Drug: nL-FLVC-001
nL-FLVC-001 is an investigational antisense oligonucleotide therapeutic sponsored by the University of Colorado Denver for the treatment of posterior column ataxia with retinitis pigmentosa (PCARP) caused by FLVCR1 gene mutations. The early phase 1 open-label study is evaluating the safety and tolerability of this RNA-targeting therapy in a single participant. The drug is designed to selectively bind mutant FLVCR1 RNA transcripts and modulate gene expression, potentially reducing disease progression. The therapy is being administered as an antisense oligonucleotide-based treatment, with the study expected to be completed by December 2028.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
Key Questions Answered in the Antisense Oligonucleotide Therapeutics Pipeline Insight Report
- Which companies/institutions are leading the antisense oligonucleotide therapeutics drug development?
- Which company is leading the antisense oligonucleotide therapeutics pipeline development activities?
- What is the current antisense oligonucleotide therapeutics commercial assessment?
- What are the opportunities and challenges present in the antisense oligonucleotide therapeutics pipeline landscape?
- What is the efficacy and safety profile of antisense oligonucleotide therapeutics pipeline drugs?
- Which company is conducting major trials for antisense oligonucleotide therapeutics drugs?
- Which companies/institutions are involved in antisense oligonucleotide therapeutics collaborations aimed at providing enhanced therapeutic alternatives for patients?
- What are the geographies covered for clinical trials in antisense oligonucleotide therapeutics?
Reasons To Buy This Report
The Antisense Oligonucleotide Therapeutics pipeline analysis report provides a strategic overview of the latest and future landscape of treatments for antisense oligonucleotide therapeutics. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into antisense oligonucleotide therapeutics collaborations, regulatory environments, and potential growth opportunities.
Related Reports
Pricing Plans
Upto 15% Off
USD
-
$1999 $1799
-
$3099 $2789
-
$4599 $3909
-
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Report Summary
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
- Selected Segments
- Printing Restrictions
- Excel Spreadsheet Delivered via Email
- Full Report
- Periodic Updates
- Post Sales Analysts Support
- Unlimited Prints
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
- All Segments
- Printing Restrictions
- PDF Delivered via Email
- Custom Report Layout
- Post Sales Analysts Support
- Periodic Updates
- Unlimited Prints
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
- All Segments
- Five Prints Available
- PDF Delivered via Email
- Limited Free Customization
- Post Sales Analyst Support
- Custom Report Layout
- Periodic Updates
- Unlimited Prints
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
- All Segments
- Unlimited Prints Available
- PDF & Excel Delivery via Email
- Limited Free Customization
- Post Sales Analysts Support
- Discount On Next Update
- Custom Report Layout
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Bundle Type
Flash Bundle
20% OFF
Number of Reports: 3
Small Business Bundle
25% OFF
Number of Reports: 5
Growth Bundle
30% OFF
Number of Reports: 8
Enterprise Bundle
35% OFF
Number of Reports: 10
Overview
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 80 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
- Life Time Access
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 100 Hours
- Complimentary Free 1 Month Subscription to Trade Data Base
- Complimentary One Month Subscription to Price Database (Chemicals only)
- Complimentary PPT Version of the Report
- Complimentary License Upgrade
- Complimentary Power BI Dashboards
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
- 3 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
- Free Analyst Hours
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
- 5 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- Complimentary Excel Data Set
- PPT Version of the Report
- Power BI Dashboards
- License Upgrade
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
- 8 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Free Analyst Hours - 80 Hours
- Power BI Dashboards
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
- 10 Reports Included
- Life Time Acess
- Analyst Support Related to Report
- PDF Version of the Report
- Complimentary Excel Data Set
- Free Analyst Hours - 50 Hours
- Free 1 Month Subscription to Trade Data Base
- 1 Month Subscription to Price Database (Chemicals only)
- License Upgrade
- Power BI Dashboards
- Free Analyst Hours - 100 Hours
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Strategic Solutions for Informed Decision-Making
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
